Search
Descriptor English: Anistreplase
Descriptor Spanish: Anistreplasa
Descriptor Portuguese: Anistreplase
Descriptor French: Anistreplase
Entry term(s): APSAC
Anisoylated Plasminogen-Streptokinase Activator Complex
BRL 26921
BRL-26921
BRL26921
Eminase
Iminase
Tree number(s): D08.811.277.656.300.760.635.075
D08.811.277.656.300.775.075
D08.811.277.656.959.350.635.075
D12.776.124.125.662.537.075
RDF Unique Identifier: https://id.nlm.nih.gov/mesh/D016255
Scope note: An acylated inactive complex of streptokinase and human lysine-plasminogen. After injection, the acyl group is slowly hydrolyzed, producing an activator that converts plasminogen to plasmin, thereby initiating fibrinolysis. Its half-life is about 90 minutes compared to 5 minutes for TPA; (TISSUE PLASMINOGEN ACTIVATOR); 16 minutes for UROKINASE-TYPE PLASMINOGEN ACTIVATOR and 23 minutes for STREPTOKINASE. If treatment is initiated within 3 hours of onset of symptoms for acute myocardial infarction, the drug preserves myocardial tissue and left ventricular function and increases coronary artery patency. Bleeding complications are similar to other thrombolytic agents.
Allowable Qualifiers: AD administration & dosage
AE adverse effects
AI antagonists & inhibitors
AN analysis
BI biosynthesis
BL blood
CF cerebrospinal fluid
CH chemistry
CL classification
CS chemical synthesis
DE drug effects
DF deficiency
EC economics
GE genetics
HI history
IM immunology
IP isolation & purification
ME metabolism
PD pharmacology
PH physiology
PK pharmacokinetics
PO poisoning
RE radiation effects
SD supply & distribution
ST standards
TO toxicity
TU therapeutic use
UL ultrastructure
UR urine
Pharm Action: Fibrinolytic Agents
Registry Number: 81669-57-0
CAS Type 1 Name: Anistreplase
Previous Indexing: Fibrinolytic Agents (1966-1990)
Plasminogen (1966-1990)
Streptokinase (1966-1990)
Public MeSH Note: 91
History Note: 91
DeCS ID: 28860
Unique ID: D016255
Documents indexed in the Virtual Health Library (VHL): Click here to access the VHL documents
Date Established: 1991/01/01
Date of Entry: 1990/05/07
Revision Date: 2016/07/01
Anistreplase - Preferred
Concept UI M0024829
Scope note An acylated inactive complex of streptokinase and human lysine-plasminogen. After injection, the acyl group is slowly hydrolyzed, producing an activator that converts plasminogen to plasmin, thereby initiating fibrinolysis. Its half-life is about 90 minutes compared to 5 minutes for TPA; (TISSUE PLASMINOGEN ACTIVATOR); 16 minutes for UROKINASE-TYPE PLASMINOGEN ACTIVATOR and 23 minutes for STREPTOKINASE. If treatment is initiated within 3 hours of onset of symptoms for acute myocardial infarction, the drug preserves myocardial tissue and left ventricular function and increases coronary artery patency. Bleeding complications are similar to other thrombolytic agents.
Preferred term Anistreplase
Entry term(s) APSAC
Anisoylated Plasminogen-Streptokinase Activator Complex
Iminase - Narrower
Concept UI M0433989
Preferred term Iminase
BRL-26921 - Narrower
Concept UI M0333009
Preferred term BRL-26921
Entry term(s) BRL 26921
BRL26921
Eminase - Narrower
Concept UI M0024830
Preferred term Eminase



We want your feedback on the new DeCS / MeSH website

We invite you to complete a survey that will take no more than 3 minutes.


Go to survey